Prestige Consumer Healthcare (PBH) investor relations material

Business overview and brand portfolio

• Operates a diversified portfolio of leading consumer healthcare brands across categories like women's health, GI, pain relief, and eye care, with several brands holding top market shares in their segments.

• Focuses on over-the-counter medicines, impacting consumers through high-volume products such as Luden's, Chloraseptic, BC, Goody's, and Monistat.

• Built the portfolio over 10-15+ years through acquisitions and organic growth, targeting 2%-3% organic growth annually.

• International segment, led by Hydralyte in Australia, represents 16% of sales and is expected to grow at 5%+ annually.

Strategic pillars and financial performance

• Three-pillar strategy: invest in brand growth, maintain strong financial profile, and allocate capital for incremental upside including M&A.

• Asset-light model with EBITDA margins in the low 30s, driving strong free cash flow and enabling flexible capital allocation.

• Achieved 3.5% total revenue growth, 2%-3% organic growth, and 9% adjusted earnings CAGR over the past five years.

• Reduced net leverage to 2.4x, with a long-term target below 3x, and repurchased $50 million in shares in fiscal 2025.

Brand building and innovation

• Uses consumer insights to drive product innovation, such as expanding Dramamine into chewables, non-drowsy, and nausea products.

• Agile marketing approach reallocates resources based on supply and demand, as seen with TheraTears, Debrox, and Stye during Clear Eyes supply constraints.

• E-commerce investments increased online sales from less than 1% in 2016 to over 16% today, leveraging content and influencer marketing.

• Annual product innovation introduces 3-5 new products, focusing on incremental improvements and logical brand adjacencies.